Research programme: serotonin 6 receptor antagonists - Suven Life Sciences

Drug Profile

Research programme: serotonin 6 receptor antagonists - Suven Life Sciences

Alternative Names: 5HT6 compounds; SUVN-501; SUVN-504; SUVN-507; SUVN-512; SUVN-623; SUVN-901; SUVN-976

Latest Information Update: 15 Jun 2017

Price : $50

At a glance

  • Originator Suven Life Sciences
  • Class Antiparkinsonians; Antipsychotics; Carbazoles; Indoles; Neuroprotectants; Obesity therapies; Small molecules; Sulfonamides; Tryptamines
  • Mechanism of Action Serotonin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Cognition disorders; Obesity; Parkinson's disease; Schizophrenia

Most Recent Events

  • 13 Jun 2017 Suven Life Sciences receives patent allowance for its Serotonin 6 receptor antagonists in the US and Australia
  • 30 Jan 2017 Suven Life Sciences has patent protection for selective 5-HT6 compounds in USA
  • 07 Dec 2016 Suven Life Sciences has patent protection for selective 5-HT6 compounds in India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top